TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vivimed Labs Limited ( (IN:VIVIMEDLAB) ) has shared an update.
Vivimed Labs Limited’s Board of Directors approved several key resolutions in their recent meeting, including the submission of unaudited financial results for the quarter ending June 30, 2025, and the re-appointment of key directors and auditors. Despite these developments, the company faces financial challenges, with a significant default in loan repayments amounting to Rs 3,748.22 million, leading to all loan accounts being classified as non-performing assets by banks. This financial strain could impact the company’s operational stability and stakeholder confidence.
More about Vivimed Labs Limited
Vivimed Labs Limited operates in the pharmaceutical industry, focusing on the production and distribution of active pharmaceutical ingredients, finished formulations, and specialty chemicals. The company primarily serves the healthcare and personal care markets.
Current Market Cap: 406.3M INR
For a thorough assessment of VIVIMEDLAB stock, go to TipRanks’ Stock Analysis page.